Ajou University School of Medicine
Suwon, 443-721, South Korea
NCT Number: NCT01489683
When not using neuromuscular blocking agent, even at optimal dosage, target-controlled infusion (TCI) of propofol and remifentanil occasionally produce unsatisfactory intubating conditions. Therefore, the investigators evaluated that the effect of tracheal lidocaine on the intubating conditions for tracheal intubation during anesthesia induction of propofol and remifentanil TCI without neuromuscular blocking agent in day-case anesthesia.
Looking for future studies?
Notify Me20 year–60 year
All sexes
Interventional
Not applicable
Suwon, 443-721, South Korea
Anesthesia was induced with propofol-remifentanil TCI with the effect-site concentration of 5μg/ml and 5ng/ml, respectively. After TCI, 3 ml of normal saline or 3 ml of 4% lidocaine was instilled to larynx and trachea, following intubation was performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 ml of 4% lidocaine was instilled to larynx and trachea
Other names: 4%lidocaine
3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
Other names: control
Time frame: baseline from 5 min of TCI was maintained
Four minutes after start of propofol-remifentanil TCI, 3 ml of normal saline or 3 ml of 4% lidocaine was instilled to larynx and trachea, and one minute later, intubation was performed in double-blinded fashion.
Ajou University School of Medicine
Other
Effect of Tracheal Lidocaine on Intubating Conditions During Propofol-remifentanil TCI Without Neuromuscular Blockade
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06020391
Drug Usage
Oslo, Norway
View Trial DetailsNCT03368456
Acquired Immunodeficiency Syndrome, Adolescent Behavior
Ypsilanti, Michigan, United States
View Trial DetailsNCT03330782
Drug Usage, Neurologic Manifestations
Suwon, Gyeonggi-do, South Korea
View Trial DetailsNCT02379455
Drug Usage
Oslo, Norway
View Trial Details